Targeting the extracellular domain of the human epidermal growth factor receptor (HER2), trastuzumab is used in different combinations for the treatment of HER2-positive breast cancer, in adjuvant and palliative settings, and also for metastatic gastric and gastroesophageal tumors. This evidence concerns the gene ERBB2 and breast cancer.